MapLight Therapeutics sets up $100 million at-the-market stock sale facility
The company entered a sales agreement with Leerink Partners allowing it to sell up to $100 million in common stock over time through an ATM offering.
SEC filing
3 stories
The company entered a sales agreement with Leerink Partners allowing it to sell up to $100 million in common stock over time through an ATM offering.
SEC filing
Release gives conflicting dates for ZEPHYR-2 and VISTA topline results; company reports $463.4 million cash position expected to fund operations through 2028.
SEC filing
The S-1, filed September 9, 2026, covers shares and pre-funded warrants sold to institutional investors in an August 2026 private placement.
SEC filing